NGM Biopharmaceuticals, Inc. Common Stock
NGM
NGM was delisted on the 4th of April, 2024.
119 hedge funds and large institutions have $833M invested in NGM Biopharmaceuticals, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 43 increasing their positions, 33 reducing their positions, and 18 closing their positions.
6,592% more call options, than puts
Call options by funds: $1.61M | Put options by funds: $24K
30% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 33
6% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 18
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
1% less funds holding
Funds holding: 120 → 119 (-1)
12% less capital invested
Capital invested by funds: $951M → $833M (-$118M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$35.6M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$27M |
| 3 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$11M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
+$9.11M |
| 5 |
Millennium Management
New York
|
+$6.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$36.9M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$11.9M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$7.03M |
| 4 |
Citigroup
New York
|
-$4.23M |
| 5 |
OCA
Octagon Capital Advisors
New York
|
-$4.2M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PL
126
Parkwood LLC
Cleveland,
Ohio
| – | -$1.05M | -50,000 | Closed |
|
127
TD Asset Management
Toronto,
Ontario, Canada
| – | -$639K | -30,400 | Closed |
|
128
Walleye Capital
New York
| – | -$470 | -22,368 | Closed |
|
129
Principal Financial Group
Des Moines,
Iowa
| – | -$307K | -14,628 | Closed |
|
130
Handelsbanken Fonder
Stockholm,
Sweden
| – | -$210K | -10,000 | Closed |
|
|
SPIA
131
Steward Partners Investment Advisory
New York
| – | -$42K | -2,000 | Closed |
|
|
CG
132
Cutler Group
San Francisco,
California
| – | -$34.5K | -1,800 | Closed |
|
|
PCM
133
Penserra Capital Management
Orinda,
California
| – | -$37K | -1,765 | Closed |
|
|
FDCDDQ
134
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| – | -$15K | -714 | Closed |
|
|
TWA
135
TCI Wealth Advisors
Tucson,
Arizona
| – | -$3K | -140 | Closed |
|
|
QCG
136
Quadrant Capital Group
Cincinnati,
Ohio
| – | -$77 | -4 | -16% |
|
|
C
137
Covestor
London,
United Kingdom
| – | +$345 | +18 | New |
|
NGM Hedge Fund Activity: Q4 2021 in Review
119 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in NGM Biopharmaceuticals, Inc. Common Stock (NGM) for Q4 2021, worth a combined $833M — down 12% from $951M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new NGM positions and 18 closed out — a net gain of 1 holder — while 43 added to existing stakes and 33 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $35.6M. The largest seller was Redmile Group, cutting an estimated $36.9M.
- 119 institutional investors held NGM Biopharmaceuticals, Inc. Common Stock (NGM) as of Q4 2021, down from 120 in Q3 2021.
- Funds reported $833M of NGM Biopharmaceuticals, Inc. Common Stock stock for Q4 2021, down 12% quarter-over-quarter.
- 19 funds opened new NGM Biopharmaceuticals, Inc. Common Stock positions in Q4 2021 and 18 closed out, a net change of +1 holder.
- The largest NGM Biopharmaceuticals, Inc. Common Stock buyer in Q4 2021 was Point72 Asset Management, an estimated $35.6M added.
- The largest NGM Biopharmaceuticals, Inc. Common Stock seller in Q4 2021 was Redmile Group, an estimated $36.9M sold.
Based on aggregated 13F filings for Q4 2021.